Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. These antibodies demonstrate superior clinical efficacy than monoclonal antibodies, indicating their role as a promising tumor immunotherapy option. Immune checkpoints are also important in tumor immunotherapy. Programmed cell death protein-1 (PD-1) is a widely acknowledged immune checkpoint target with effective anti-tumor activity. PD-1 inhibitors have demonstrated notable therapeutic efficacy in treating hematological and solid tumors; however, more than 50% of patients undergoing this treatment exhibit a poor response. However, ICI-based combination therapies (ICI combination therapies) have been demonstrated to synergistically increase anti-tumor effects and immune response rates. In this review, we compare the clinical efficacy and side effects of BSABs and ICI combination therapies in real-world tumor immunotherapy, aiming to provide evidence-based approaches for clinical research and personalized tumor diagnosis and treatment.

中文翻译：

---

双特异性抗体与免疫检查点阻断联合疗法在癌症中的功效和安全性：真实世界比较

新兴的肿瘤免疫治疗方法包括双特异性抗体（BSAB）、免疫检查点抑制剂（ICIs）和过继性细胞免疫疗法。 BSAB属于可以特异性识别两种不同抗原或同一抗原上的表位的抗体家族。这些抗体表现出比单克隆抗体更优异的临床疗效，表明它们作为一种有前途的肿瘤免疫治疗选择的作用。免疫检查点在肿瘤免疫治疗中也很重要。程序性细胞死亡蛋白-1 (PD-1) 是一种广泛认可的免疫检查点靶标，具有有效的抗肿瘤活性。 PD-1抑制剂在治疗血液肿瘤和实体瘤方面表现出显着的疗效；然而，超过 50% 接受这种治疗的患者反应不佳。然而，基于ICI的联合疗法（ICI组合疗法）已被证明可以协同提高抗肿瘤效果和免疫应答率。在这篇综述中，我们比较了 BSAB 和 ICI 联合疗法在现实世界肿瘤免疫治疗中的临床疗效和副作用，旨在为临床研究和个性化肿瘤诊断和治疗提供循证方法。